Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background and Rationale: Memory is impaired in Parkinson's Disease. Acetylcholine (ACh) is a neurotransmitter in the brain. ACh function is impaired in Parkinson's Disease. ACh is important for normal memory function. Like PD, ACh function is impaired in Alzheimer's disease where ACh treatment improves memory function. Thus, ACh treatment may improve memory in PD. Study Questions: Will administration of a drug that increases ACh levels in the brain improve memory and brain function in Parkinson's Disease? Design: Double-blind, placebo controlled study of 10mg Donepezil daily for 8 weeks. Study Population: Subjects with Parkinson's disease who are not demented. Outcome measures: 1. Brain function during a sequence learning memory task. Brain function will be measured by Positron Emission Tomography. 2. Multiple behavioral measures of memory including rate of new information acquisition, rate of retrieval of learned information, and rate of forgetting information.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR018535-04
Application #
7377111
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
4
Fiscal Year
2006
Total Cost
$4,632
Indirect Cost

  Institution

Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030

  Publications

DeRosse, Pamela; Nitzburg, George C; Blair, Melanie et al. (2018) Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res 195:385-390
Lyall, A E; Pasternak, O; Robinson, D G et al. (2018) Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning. Mol Psychiatry 23:701-707
Tarnawski, Laura; Reardon, Colin; Caravaca, April S et al. (2018) Adenylyl Cyclase 6 Mediates Inhibition of TNF in the Inflammatory Reflex. Front Immunol 9:2648
Shafritz, Keith M; Ikuta, Toshikazu; Greene, Allison et al. (2018) Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav :
Damle, Nishad R; Ikuta, Toshikazu; John, Majnu et al. (2017) Relationship among interthalamic adhesion size, thalamic anatomy and neuropsychological functions in healthy volunteers. Brain Struct Funct 222:2183-2192
McNamara, Robert K; Szeszko, Philip R; Smesny, Stefan et al. (2017) Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence. Neuroscience 343:423-433
Kafantaris, Vivian; Spritzer, Linda; Doshi, Vishal et al. (2017) Changes in white matter microstructure predict lithium response in adolescents with bipolar disorder. Bipolar Disord 19:587-594
DeRosse, Pamela; Ikuta, Toshikazu; Karlsgodt, Katherine H et al. (2017) White Matter Abnormalities Associated With Subsyndromal Psychotic-Like Symptoms Predict Later Social Competence in Children and Adolescents. Schizophr Bull 43:152-159
Schwehm, Andrew; Robinson, Delbert G; Gallego, Juan A et al. (2016) Age and Sex Effects on White Matter Tracts in Psychosis from Adolescence through Middle Adulthood. Neuropsychopharmacology 41:2473-80
Cui, X; Zhang, L; Magli, A R et al. (2016) Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. Leukemia 30:74-85

Showing the most recent 10 out of 230 publications